[Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by cycloferon].
The peculiarities of immunologic processes and immunocorrecting potential of Cyclopheron were studied in 62 patients with preclinical epileptogenesis. Using clinical, EEG and biochemical examination, expression of epileptogenesis was estimated as regressed, compensated, increasing, decompensated. Preclinical stage of epilepsy was accompanied by disturbance of immunological brain reactivity the expression of which was correlated with a level of compensative epileptogenesis manifestation. The decrease of the latter is followed by intensive disintegration of neuroimmune interactions characterized by immunodeficiency of mixed type with significant presentation of neuroimmune disturbances. Therefore, a use of Cyclopheron, as a medication with multilevel immuno-correcting action, is expedient at initial stage of epilepsy.
Gromov
S A
SA
Khorshev
S K
SK
Bessmel'tsev
S S
SS
Korsakova
E A
EA
Poliakov
Iu I
IuI
D000166:Acridines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D016207:Cytokines / Q000097:blood; D004569:Electroencephalography; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D017709:Fractals; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008214:Lymphocytes / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D015213:Neuroimmunomodulation
D000166:Acridines; D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D016207:Cytokines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007073:Immunoglobulin E; C026430:10-carboxymethyl-9-acridanone